Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

The development of targeted therapy for patients with Multiple Myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chr1q (Amp1q) is the most frequent arm-level copy number gain in patients with MM, and it is associated with higher risk of progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sklavenitis-Pistofidis, Romanos, Lightbody, Elizabeth D., Reidy, Mairead, Tsuji, Junko, Aranha, Michelle P., Heilpern-Mallory, Daniel, Huynh, Daisy, Chong, Stephen J. F., Hackett, Liam, Haradhvala, Nicholas J., Wu, Ting, Su, Nang K., Berrios, Brianna, Alberge, Jean-Baptiste, Dutta, Ankit, Davids, Matthew S., Papaioannou, Maria, Getz, Gad, Ghobrial, Irene M., Manier, Salomon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418223/
https://www.ncbi.nlm.nih.gov/pubmed/37577538
http://dx.doi.org/10.1101/2023.08.01.551480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418223/
https://www.ncbi.nlm.nih.gov/pubmed/37577538
http://dx.doi.org/10.1101/2023.08.01.551480

Ejemplares similares